January 3, 2018 / 9:33 PM / 6 months ago

BRIEF-Ascendis Pharma Says Completed Target Enrollment In Phase 3 Trial Of Pediatric Growth Hormone Deficiency Treatment

Jan 3 (Reuters) - Ascendis Pharma A/S:

* ASCENDIS PHARMA ANNOUNCES COMPLETION OF TARGET ENROLLMENT IN PHASE 3 TRIAL OF TRANSCON GROWTH HORMONE FOR PEDIATRIC GROWTH HORMONE DEFICIENCY

* ASCENDIS PHARMA - TOP-LINE RESULTS FROM PHASE 3 HEIGHT TRIAL OF TRANSCON GROWTH HORMONE ANTICIPATED IN Q1 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below